The World Market for Psychiatric Drugs

Published by: PJB Publications USA Inc.

Published: Sep. 1, 2001 - 150 Pages

Table of Contents

1.1 Scope of the Report


1.2 Methodology


1.3 Overview of Psychiatric Disorders


1.4 Overview of Psychiatric Drugs


1.5 The World and U.S. Markets for Psychiatric Drugs

2. The Nervous System and Psychiatric Disorders

2.1 The Nervous System


2.1.1 Neurons


2.1.2 Neuroglia


2.1.3 Neurotransmitters


2.2 Major Depressive Disorder


2.3 Schizophrenia


2.4 Anxiety Disorders


2.4.1 Generalized Anxiety Disorder


2.4.2 Obsessive Compulsive Disorder


2.4.3 Panic Disorder


2.4.4 Phobias


2.4.5 Post-Traumatic Stress Disorder


2.5 Bipolar Disorder


2.6 Attention Deficit Hyperactivity Disorder


2.7 Eating Disorders


2.7.1 Anorexia Nervosa


2.7.2 Bulimia Nervosa


2.8 Sleep Disorders


2.8.1 Insomnia


2.8.2 Narcolepsy


2.9 Substance-Related Disorders


2.10 Alzheimer's Disease

3. Psychopharmacologic Agents on the Market

3.1 Antidepressants


3.1.1 Monoamine Oxidase Inhibitors


3.1.2 Selective Serotonin Reuptake Inhibitors


3.1.3 Serotonin and Norepinephrine Reuptake Inhibitors


3.1.4 Tricyclic Antidepressants


3.2 Antipsychotic Agents


3.3 Antianxiety Agents


3.3.1 Benzodiazepines


3.3.2 Nonbenzodiazepines


3.4 Antimanic Agents


3.4.1 Lithium


3.5 ADHD Agents


3.5.1 Amphetamines


3.5.2 CNS Stimulants


3.6 Substance-Related Disorder Agents


3.7 Alzheimer's Disease Agents

4. Psychopharmacologic Agents in Development

4.1 Antidepressants in Development


4.2 Antipsychotic Agents in Development


4.3 Antianxiety Agents in Development


4.4 Antimanic Agents in Development


4.5 ADHD Agents in Development


4.6 Alzheimer's Disease Agents in Development

5. The Market for Psychiatric Drugs

5.1 Market Forecast Methodology


5.2 Overall World and U.S. Psychiatric Drug Markets


5.2.1 Market Description


5.2.2 World Market Size and 5-Year Forecast


5.2.3 U.S. Market Size and 5-Year Forecast


5.3 Antidepressants


5.3.1 World Market Size and 5-Year Forecast


5.3.2 U.S. Market Size and 5-Year Forecast


5.3.3 Competitor Market Share


5.3.4 Market Growth Factors


5.4 Antipsychotic Agents


5.4.1 World Market Size and 5-Year Forecast


5.4.2 U.S. Market Size and 5-Year Forecast


5.4.3 Competitor Market Share


5.4.4 Market Growth Factors


5.5 Antianxiety Agents


5.5.1 World Market Size and 5-Year Forecast


5.5.2 U.S. Market Size and 5-Year Forecast


5.5.3 Competitor Market Share


5.5.4 Market Growth Factors


5.6 Antimanic Agents


5.6.1 World Market Size and 5-Year Forecast


5.6.2 U.S. Market Size and 5-Year Forecast


5.6.3 Competitor Market Share


5.6.4 Market Growth Factors


5.7 ADHD Agents


5.7.1 World Market Size and 5-Year Forecast


5.7.2 U.S. Market Size and 5-Year Forecast


5.7.3 Competitor Market Share


5.7.4 Market Growth Factors


5.8 Substance-Related Disorder Agents


5.8.1 World Market Size and 5-Year Forecast


5.8.2 U.S. Market Size and 5-Year Forecast


5.8.3 Competitors


5.8.4 Market Growth Factors


5.9 Alzheimer's Disease Agents


5.9.1 World Market Size and 5-Year Forecast


5.9.2 U.S. Market Size and 5-Year Forecast


5.9.3 Market Growth Factors

6. Company Profiles

6.1 Abbott Laboratories


6.2 ALZA Corp.


6.3 AstraZeneca Pharmaceuticals LP


6.4 Aventis Pharmaceuticals Inc.


6.5 Baxter Healthcare Corp.


6.6 Boehringer Ingelheim Corp.


6.7 Bristol-Myers Squibb Co.


6.8 Celltech Group plc


6.9 Cephalon, Inc.


6.10 Cortex Pharmaceuticals, Inc.


6.11 DuPont Pharmaceuticals Co.


6.12 Eli Lilly and Co.


6.13 Endo Pharmaceuticals Inc.


6.14 First Horizon Pharmaceutical Corp.


6.15 Forest Laboratories, Inc.


6.16 GlaxoSmithKline


6.17 ICN Pharmaceuticals, Inc.


6.18 Janssen Pharmaceutica


6.19 Johnson & Johnson


6.20 Mallinckrodt Inc.


6.21 Merck & Co., Inc.


6.22 Neurogen Corp.


6.23 NeuroSearch A/S


6.24 Novartis Pharmaceuticals Corp.


6.25 Organon Inc.


6.26 Pfizer Inc.


6.27 Pharmacia Corp.


6.28 Roche Laboratories Inc.


6.29 Roxane Laboratories, Inc.


6.30 Sanofi-Synthelabo Inc.


6.31 Schering-Plough Corp.


6.32 Shire Pharmaceuticals Group plc


6.33 Solvay Pharmaceuticals, Inc.


6.34 Synaptic Pharmaceutical Corp.


6.35 Watson Pharmaceuticals, Inc.


6.36 Wyeth-Ayerst Pharmaceuticals (American Home Products)

7. Company Directory

Abstract

But: Where is the next Prozac?

The World Market for Psychiatric Drugs, from Theta Reports, cuts through the hundreds of compounds in development, surveying only the key advances. The report reviews treatments for a variety of neurological and psychological disorders, including:

• Depression
• Schizophrenia
• ADHD
• Bipolor disorder
• Anxiety disorders
• Anorexia and bulimia nervosa
• Substance abuse
• Alzheimer's disease.

The report thoroughly analyzes these segments, providing essential data and analysis on the most important players and most important therapies. Specific questions answered include:

• Which drugs will be blockbusters in their respective therapeutic areas?
• Which disease areas hold the most commercial promise?
• Which companies are aggressively positioning themselves to seize market leadership?

Illustrated with detailed tables and full-color charts, The World Market for Psychiatric Drugs cuts through the mass of raw data and gives you the value-added analysis to make the right strategic decisions in this highly competitive market.

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.